Patents by Inventor Wael Tadros

Wael Tadros has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240018274
    Abstract: Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.
    Type: Application
    Filed: June 21, 2023
    Publication date: January 18, 2024
    Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
  • Patent number: 11773187
    Abstract: Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: October 3, 2023
    Assignee: NantBio, Inc.
    Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
  • Publication number: 20230039169
    Abstract: Recombinant cells and methods therefor are contemplated that allow for rapid and high titer production of recombinant viruses, and especially replication deficient Ad5 virus. In some preferred aspects, the host cell is modified to produce an inhibitor that reduces or eliminates the expression of a therapeutic protein encoded in the virus, while in other aspects, the virus includes a gene that directly or indirectly reduces or eliminates the expression of a therapeutic protein encoded in the virus. Most preferably, shRNA encoded by the host cell will reduce or suppress expression of a payload gene encoded in the recombinant virus.
    Type: Application
    Filed: September 15, 2022
    Publication date: February 9, 2023
    Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
  • Patent number: 11485957
    Abstract: Recombinant cells and methods therefor are contemplated that allow for rapid and high titer production of recombinant viruses, and especially replication deficient Ad5 virus. In some preferred aspects, the host cell is modified to produce an inhibitor that reduces or eliminates the expression of a therapeutic protein encoded in the virus, while in other aspects, the virus includes a gene that directly or indirectly reduces or eliminates the expression of a therapeutic protein encoded in the virus. Most preferably, shRNA encoded by the host cell will reduce or suppress expression of a payload gene encoded in the recombinant virus.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: November 1, 2022
    Assignee: NantBio, Inc.
    Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
  • Publication number: 20210032371
    Abstract: Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.
    Type: Application
    Filed: January 15, 2019
    Publication date: February 4, 2021
    Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
  • Publication number: 20200354687
    Abstract: Recombinant cells and methods therefor are contemplated that allow for rapid and high titer production of recombinant viruses, and especially replication deficient Ad5 virus. In some preferred aspects, the host cell is modified to produce an inhibitor that reduces or eliminates the expression of a therapeutic protein encoded in the virus, while in other aspects, the virus includes a gene that directly or indirectly reduces or eliminates the expression of a therapeutic protein encoded in the virus. Most preferably, shRNA encoded by the host cell will reduce or suppress expression of a payload gene encoded in the recombinant virus.
    Type: Application
    Filed: October 9, 2018
    Publication date: November 12, 2020
    Applicant: NantBio, Inc.
    Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
  • Publication number: 20200087680
    Abstract: The present disclosure relates to recombinant sensor cells comprising an AND gate such that an expressible sequence (e.g., a reporter gene) is expressed after the occurrence of two separate triggering events. Nucleic acids, kits, and methods for making and using the recombinant sensor cells are also disclosed herein.
    Type: Application
    Filed: September 12, 2019
    Publication date: March 19, 2020
    Inventors: Kayvan Niazi, Wael Tadros, Clifford Anders Olson, Nicholas James Witchey